Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine

Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine Cimeio Therapeutics, a biotechnology company that is reimagining immunotherapy with its Shielded Cell and Immunotherapy (SCIP®)…

Read MoreCimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine

United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs

United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the achievement of two milestones for its xenotransplantation…

Read MoreUnited Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs

Thought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet

Thought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet The Zayed Prize for Sustainable Development, the UAE’s pioneering prize…

Read MoreThought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Ligand Pharmaceuticals Incorporated announced that…

Read MoreLigand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful progression-free survival benefits in patients with HR-positive, HER2-low, or negative breast cancer in the TROPION-Breast01 Phase III trial

Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low, or negative breast cancer in TROPION-Breast01 Phase III trial Positive high-level results from the TROPION-Breast01…

Read MoreDatopotamab deruxtecan demonstrated a statistically significant and clinically meaningful progression-free survival benefits in patients with HR-positive, HER2-low, or negative breast cancer in the TROPION-Breast01 Phase III trial

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer Bristol Myers Squibb today announced the…

Read MoreBristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer Merck (NYSE: MRK), known as…

Read MoreMerck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

Emulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment

Emulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment Emulate, Inc., the leading provider of next-generation in vitro models, today announced the publication…

Read MoreEmulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment